There is no maximum time limit for staying on Ocrevus. The FDA-approved prescribing information does not specify a cap on treatment duration, and clinical trial data now extends beyond 10 years of continuous use. Most people remain on Ocrevus indefinitely as long as it continues working and side effects remain manageable, though some patients and their neurologists eventually discuss stopping based on age and disease stability.
What 10-Year Data Shows
The longest clinical trial data on Ocrevus now covers over a decade of continuous treatment. Among people with relapsing MS who stayed on the drug for 10 years, 76.6% remained free from confirmed disability progression and 91.9% did not need a walking aid. For people with primary progressive MS, the numbers are more modest but still meaningful: 80.4% did not need a wheelchair after 10 years of treatment.
These results come from open-label extension studies, meaning people who responded well in the original trials chose to keep going. That introduces some selection bias, since patients who had problems likely dropped out earlier. Still, the data confirms that the drug can remain effective for at least a decade without losing its punch.
Safety Over Many Years
Long-term safety data covers more than 6,100 patients across 12 clinical trials, totaling over 28,000 patient-years of exposure. Serious infections occurred at a rate of about 3 per 100 patient-years, and malignancies at about 0.5 per 100 patient-years. Both rates fall within the range seen in broader MS populations tracked through real-world registries, meaning Ocrevus does not appear to add significant extra risk for these outcomes over time.
The main long-term concern is what happens to your immune system after years of B-cell depletion. Ocrevus works by wiping out a specific type of immune cell, and over time, your levels of immunoglobulin G (a key antibody your body uses to fight infections) can gradually drop. The prescribing label notes an association between decreased immunoglobulin levels and higher rates of serious infections, particularly after about seven years. Your neurologist will monitor your immunoglobulin levels periodically while you’re on treatment, and a sustained decline might factor into decisions about continuing.
How Vaccines Work on Long-Term Treatment
Years of B-cell depletion does reduce your ability to generate antibodies in response to vaccines. Research on COVID-19 vaccination found that people on Ocrevus produced weaker antibody responses compared to healthy controls. However, they mounted a robust response from the other arm of the immune system, T cells, which Ocrevus does not directly target. In practice, this translated to real protection: infection rates after vaccination were similar between people on Ocrevus and healthy controls (about 49% vs. 47%), and roughly 80% of vaccinated patients who did get infected experienced only mild illness.
The takeaway is that vaccines still offer meaningful protection while you’re on Ocrevus, even if blood tests suggest a weaker antibody response. Timing vaccines about four to five months after your last infusion, before the next one, can help maximize your response.
Extended Dosing Intervals
The standard schedule is one infusion every six months, but a growing body of evidence suggests that some patients can safely stretch that interval. A study published in Neurology looked at patients who went eight months or longer between infusions and found no meaningful increase in disease activity. Among relapsing MS patients with extended intervals, only 2.2% developed new lesions on MRI, and relapse rates were nearly identical to those on the standard schedule. No patients with progressive MS had any breakthrough MRI activity at all.
Extended dosing isn’t officially recommended in the prescribing label, but many neurologists are adopting it for patients who’ve been stable for several years. Longer gaps between infusions may help reduce the cumulative impact on immunoglobulin levels and infection risk, which becomes increasingly relevant the longer you stay on the drug.
When Stopping Becomes an Option
For some patients, the question isn’t just how long you can stay on Ocrevus but whether you still need it. The inflammatory component of MS tends to decrease naturally with age, which has led to growing interest in discontinuing treatment for older, stable patients.
The DISCOMS trial, which informed current thinking, established that stopping disease-modifying therapy can be reasonably considered for patients older than 55 who have had stable MS for at least five years, with no relapses in five years and no new MRI lesions in three years. Cleveland Clinic neurologists have cautioned, though, that most participants in that trial were on older injectable medications. Ocrevus and similar modern therapies carry a potential risk of disease rebound upon stopping, so the results may not directly apply.
This means the decision to stop Ocrevus is highly individual. A 60-year-old with no disease activity for a decade is in a very different position than a 45-year-old who had a relapse three years ago. Factors that weigh into the conversation include your age, how long you’ve been stable, your immunoglobulin trends, your infection history, and your comfort with the uncertainty of stopping.
What This Means in Practice
Most people on Ocrevus stay on it for years, and the data supports doing so. There is no built-in expiration date on treatment. The practical ceiling isn’t a fixed number of years but rather a set of clinical signals: falling immunoglobulin levels, recurring infections, or reaching an age and stability profile where the risks of continued immune suppression start to outweigh the benefits of staying on therapy. For many patients, that inflection point never arrives, and they continue treatment indefinitely with regular monitoring.